Met (Sigma‐Aldrich, Shanghai, China) and EX 527 (Abcam, ab141506, Shanghai, China) were dissolved in 1% dimethyl sulfoxide (DMSO, Sigma‐Aldrich) with 0.1 M phosphate buffer solution (PBS). Rats were intraperitoneally given 3, 10, 0 mg/kg/d Met or DMSO (0.1 M PBS + 1% DMSO). The total volume was 100 μl. In the in vitro experiment, BV2 cells were treated with Met (3, 10, 30 μg/ml) for 24 h after undergoing OGD/R for 24 h.
Ex 527
Manufactured by Abcam
Sourced in United States
EX 527 is a drug-like small molecule that inhibits the enzyme SIRT1. It is commonly used in research applications to investigate the biological functions of SIRT1.
Automatically generated - may contain errors
Lab products found in correlation
Auy922, by Enzo Life Sciences (2 mentions)
17 aag, by Enzo Life Sciences (2 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
Rh ghrelin, by Abcam (1 mentions)
Msppoh, by Cayman Chemical (1 mentions)
Fitc mouse anti human cd44, by BD (1 mentions)
Rpmi medium, by Thermo Fisher Scientific (1 mentions)
Heat inactivated fbs, by Thermo Fisher Scientific (1 mentions)
Penicillin, by Merck Group (1 mentions)
Streptomycin, by Merck Group (1 mentions)
7 protocols using ex 527
1
Metformin Neuroprotection in Ischemia-Reperfusion
2
Intranasal Ghrelin and Inhibitor Effects on Hypoxic-Ischemic Injury
3
Cytoprotective Effects of EDPs and DHA
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HL-1 cells subjected to H/R or normoxia were treated/co-treated with the following pharmacological agents: 19,20-EDP (1 μM), DHA (100 μM), N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MSPPOH, 50 μM), selective pharmacological inhibitor of CYP epoxygenase activity blocking formation of endogenous EDPs from DHA and EX-527 (1 μM) inhibitor of SIRT1 enzymatic activity. Stock solutions of 19,20-EDP, DHA, MSPPOH, and EX-527 were prepared in 100% ethanol. Final concentrations of both solvents were less than 0.01% of the treatment solutions. EX-527 was purchased from Abcam, Cambridge, UK. 19,20-EDP, DHA, and MSPPOH were obtained from Cayman Chemical, Ann Arbor, MI, USA.
4
Intranasal TC-G 1008 and Intraperitoneal EX527 in HIE
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TC-G 1008 (5, 15, 45 mg/kg, Tocris Bioscience, USA) was administered intranasally [32 (link)]. A total of 6 μl of TC-G 1008 or DDH2O was given every 2 min in alternating nares. EX527 (10 mg/kg, abcam, USA), or DMSO was injected intraperitoneally at 1 h before HIE. GPR39 CRISPR (Santa Cruz Biotechnology, USA), PGC-1α CRISPR (Santa Cruz Biotechnology, USA), or control CRISPR (Santa Cruz Biotechnology, USA) were given intracerebroventricularly (1.5 mm anterior, 1.5 mm lateral to the Bregma, and 1.7 mm deep on the ipsilateral hemisphere) at 48 h before HIE induction.
5
SIRT1 Inhibitor ex-527 Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
SIRT1 specific inhibitor ex-527 (Abcam, Cambridge, MA, USA) was dissolved in dimethyl sulfoxide to form a 100 mM stock solution. The effects of ex-527 were evaluated on CEWH at a working concentration of 100 µM diluted by saline solution according to the previous research in vivo.24 (link) Ten microliters ex-527 working solutions were administered topically to the right injured corneas using pipettes every six hours after corneal epithelial debridement. Saline solution treatment of the left injured corneas served as the control. After 24 hours, the recovery of corneal epithelia was examined.
In HCECs, 10 µM ex-527 was added to the cells, and dimethyl sulfoxide treatment was used as the control. After 24 hours treatment, the cells were subjected to further experiments.
In HCECs, 10 µM ex-527 was added to the cells, and dimethyl sulfoxide treatment was used as the control. After 24 hours treatment, the cells were subjected to further experiments.
6
Multidrug-Resistant Cancer Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CEM human lymphoblastic leukemia cell line and its MDR variants, CEM/VLB55–8, and CEM/VLB100 [33 (link)], HeyA8 human ovarian cancer cell line and its MDR subline HeyA8-MDR, MCF-7 human breast cancer cell line and its MDR variant MCF7-MDR (originally named MCF-7/Adr) cells [34 (link)] were kindly provided by Dr. Fiedler (MD Anderson, TX, USA). 17-AAG and AUY922 were purchased from Enzo Life Sciences Inc. (Farmingdale, New York, USA) and Selleck Chemicals (Houston, TX, USA), respectively. EX527 was purchased from BioVision Inc. (Milpitas, CA, USA). Amurensin G, a natural SIRT1 inhibitor, was supplied Dr. Oh (Seoul National University, Seoul, Korea) as described previously [35 (link)].
7
Isolation and Characterization of CD44-Expressing Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human K562 CML cell line was obtained from American Type Culture Collection (Manassas, VA). CD44high K562 cells were established during isolation of imatinib-resistant K562 cells after treatment with increasing concentrations of imatinib, and were stable in complete medium without imatinib. The profile of cell surface CD44 expression was carried out on both cells and gated using mouse anti-human CD44-FITC (BD Biosciences, San Jose, CA, USA).We also used CD44+ HCT-15 cells with high CD44 expression and CD44- HCT-15 cells with low CD44 expression isolated from human colon cancer cell line HCT-15 29 (link). Cells were maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v⁄v) heat-inactivated FBS (Gibco BRL, Life Technologies, Carlsbad, CA, USA), 100 U⁄ml penicillin and 100 mg⁄ml streptomycin (Sigma-Aldrich, St.Louis, MO, USA) in a 5% CO2 humidified incubator at 37°C. 17-AAG and AUY922 were purchased from Enzo Life Sciences Inc. (Farmingdale, New York, USA) and Selleck Chemicals (Houston, TX, USA), respectively. EX527 was purchased from BioVision Inc. (Milpitas, CA, USA). Amurensin G, a natural SIRT1 inhibitor, was supplied Dr. Oh (Seoul National University, Seoul, Korea) as described previously 30 (link).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!